Imaging3, Inc.

(Public, OTC:IMGG)

A new and radical medical device from Imaging3 Inc. (OTC:IMGG) is ready to set the standard, and revolutionize the way we look at X-ray, MRI and CT scans. Imaging 3 is currently awaiting FDA approval on their DViS (Dominion Volumetric Imaging Scanner). Currently, medical imaging is met with challenges of long waits, lack of space, lack of mobility, and limited uses. However, for the first time ever, health-care workers will be able to instantly view 3D, high-resolution images of virtually any part of the human body. Thus, Imaging 3 looks to change all that. Saving time, saving lives and reducing costs. This technology will “set the standard for the next 10 years.” The following article was composed by StocksHaven Investments alongside Professor Philip Runfeldt, a Behavioral Analyst who has worked with Fortune 500 companies and major Universities throughout

...

Advanced Medical Isotope Corporation (ADMD.PK) develops advanced production systems and processes in the nuclear medicine industry. The Company’s primary focus is on making previously unavailable medical isotopes, such as radioisotopes and stable isotopes, more available to the medical marketplace. In addition, the company leads the way to advanced systems for local product production. The company encourages using less invasive therapeutic processes, liked medical imaging, rather than highly invasive surgical approaches in the diagnosis and treatment of diseases like cancer.

Advanced Medical has the rights to an advanced design compact system. This system is used in a series of medical radioisotopes for the advancement of medical imaging diagnostics. Positron Emission Tomography, also known as PET scanning, or imaging, is a newer diagnostic imaging device. PET scans are used to identify, isolate and target cancerous growths. Using Advanced Medical’s isotopes reduces the process losses that occur when using isotopes produced in a

...

Trading on the NASDAQ Capital Market, iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions. Headquartered in Nashua, New Hampshire, with additional offices in Beavercreek, Ohio, their solutions enable healthcare professionals to serve patients better by identifying pathologies and pinpointing cancer earlier. The Company’s solutions aid in the early detection of the most prevalent cancers.

The Company received Food and Drug Administration (FDA) approval of their first breast-cancer detection product in 2002. Since then they placed more than 2,700 iCAD systems in healthcare practices around the globe. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems, and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Their systems are for the high, mid, and low volume mammography markets.

iCAD’s mammography CAD innovations include being the first system to offer a clear film-to-digital upgrade path, as well as the

...

Imaging3, Inc. (IMGG.OB), a medical device manufacturer and distributor, has developed a breakthrough technology that utilizes high-resolution photo-flouroscopy to produce three-dimensional medical diagnostic images. With its ability to produce real-time 3D images, Dominion™ can be used to improve any medical procedure where multiple frame references are required to perform surgery on or in the human body.

The Dominion’s patented technology can be applied to a multitude of medical areas including trauma, cardiology, pediatrics, orthopedics, vascular, neuro-vascular, and sports medicine. The real-time 3D images will allow surgeons to plan for less invasive and more precise procedures, which will reduce a patient’s risk and recovery time. In addition to 3D real-time flouroscopic imaging, the Dominion can also emulate other imaging technology, like a CT scan. Along with its high-resolution imaging capabilities, the Dominion is a mobile unit that can fit that is powered by a standard wall outlet and will fit through

...

Zacks medical devices analyst Tom Park was on hand recently to give us an update on companies engaged in developing the medical procedure tools entering the market in the years to come. We focused on his two most recent updates.

Can we start by talking about companies you’ve been working on recently? What’s the latest company you’ve issued a report on?

Vital Images, Inc. (VTAL) develops medical software for use primarily in clinical diagnosis, disease screening and therapy planning. The company's software applies proprietary computer graphics and image processing technologies to a wide variety of data supplied by computed tomography (CT), magnetic resonance (MR), and positron emission tomography (PET) scanners.

What was the verdict?

Results continue to be impacted by the slowdown in the CT market and greater-than-expected impact from the Deficit Reduction Act. We again lowered our FY08 EPS estimate. Management reiterated its FY08 revenue and EPS guidance. Our

...

Vital Images, Inc. (VTAL) develops medical software for use primarily in clinical diagnosis, disease screening and therapy planning. The company's software applies proprietary computer graphics and image processing technologies to a wide variety of data supplied by computed tomography (CT), magnetic resonance (MR), and positron emission tomography (PET) scanners.

After this year, the company expects to once again generate strong growth by capturing a growing share of customers in an expanding worldwide market for three-dimensional medical imaging products. However, the company's ability to maintain high gross margins is at risk from its dependence on Toshiba, which is expected to increase.

The company's sound cash position is being utilized for stock repurchases and may lead to an acquisition over the long-term. We believe VTAL is appropriately valued at roughly a group premium of 3.3x 2009 revenue estimate. Our price target moves to $17.50, and our Hold rating is maintained.

Read the

...

Digirad Corporation (NASDAQ: DRAD) announced Friday the beginning of trials on a new medical imaging system, which will use proprietary technology to correct image distortion. The company says its new Cardius X-ACT system is expected to be available for sale in mid-2009, pending required regulatory approvals.

Attenuation, or image correction, is a common issue in myocardial perfusion imaging, also known as cardiac imaging based on SPECT (single photon emission computed tomography). The process to capture images includes injection of small amounts of radioactive substances, which can then be tracked.

Solutions to lessening attenuation already exist, said Richard Conwell, senior vice president of technology, “but they involve tradeoffs, such as “noisy” images, truncated scans, lengthy procedures with risk of excess movement by patients, or higher levels of radiation dosage.”

SPECT images are used to identify blockages in coronary arteries, evaluate risk of a heart attack, and assess a patient’s condition after major heart surgery.

...